Brief: Chemomab Reports Top-Line Results From Cm-101 Phase 2A Liver Fibrosis Biomarker Trial In Nash Patients

Chemomab Therapeutics

03/01/2023 13:22

Jan 3 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB REPORTS TOP-LINE RESULTS FROM CM-101 PHASE 2A
LIVER
FIBROSIS BIOMARKER TRIAL IN NASH PATIENTS
    * CHEMOMAB THERAPEUTICS LTD - CM-101 MET PRIMARY ENDPOINT
    * CHEMOMAB- CM-101 ACHIEVED REDUCTIONS IN SECONDARY
ENDPOINTS
INCLUDING LIVER FIBROSIS BIOMARKERS, PHYSIOLOGIC ASSESSMENTS
MEASURED AT BASELINE, WEEK 20

Source text for Eikon:  ID:nPn3KWbcna 
Further company coverage:  CMMB.O 
 ((Reuters.Briefs@thomsonreuters.com;))